DrugPatentWatch Database Preview
Ge Healthcare Company Profile
What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?
There are seven US patents protecting GE HEALTHCARE drugs.
There are one hundred and thirteen patent family members on GE HEALTHCARE drugs in thirty-one countries and seventy-three supplementary protection certificates in fifteen countries.
Summary for Ge Healthcare
| International Patents: | 113 |
| US Patents: | 7 |
| Tradenames: | 62 |
| Ingredients: | 42 |
| NDAs: | 54 |
| Drug Master File Entries: | 5 |
| Patent Litigation for Ge Healthcare: | See patent lawsuits for Ge Healthcare |
Drugs and US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | MYOVIEW | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-001 | Feb 9, 1996 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Ge Healthcare | SODIUM IODIDE I 123 | sodium iodide i-123 | CAPSULE;ORAL | 017630-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Ge Healthcare | OMNIPAQUE 12 | iohexol | SOLUTION;ORAL | 018956-009 | Apr 17, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Ge Healthcare | HYPAQUE | diatrizoate meglumine | INJECTABLE;INJECTION | 016403-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | 4,396,597 | ➤ Sign Up |
| Ge Healthcare | OMNIPAQUE 140 | iohexol | INJECTABLE;INJECTION | 018956-005 | Nov 30, 1988 | 4,250,113 | ➤ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | RE36418 | ➤ Sign Up |
| Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | 5,529,766 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for Ge Healthcare
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,854,920 | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | ➤ Sign Up |
| 5,558,854 | Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas | ➤ Sign Up |
| 5,573,751 | Persistent gaseous bubbles as ultrasound contrast media | ➤ Sign Up |
| 9,833,458 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Ge Healthcare Drugs
Supplementary Protection Certificates for Ge Healthcare Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB03/033 | United Kingdom | ➤ Sign Up | PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321 |
| 2009 00036 | Denmark | ➤ Sign Up | PRODUCT NAME: PACLITAXELALBUMIN |
| C/GB07/011 | United Kingdom | ➤ Sign Up | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 15/005 | Ireland | ➤ Sign Up | PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
